Modelling Human Leukemia and Lymphoma in Severe Combined Immunodeficient (Scid) Mice: Practical Applications

miR-378 inhibits cell growth and enhances apoptosis in human myelodysplastic syndromes

“…However, the initiation and development of cancer is not only related to the characteristics of the cancer cells, but also closely related to the complex interaction between the cancer and the host or the microenvironment in vivo (33). The immunodeficient mouse models, especially those of SCID mice and NOD/SCID mice, have been used to study the growth and tumorigenesis of hematological malignant tumors in vivo (34,35). In order to determine whether miR-378 overexpression could affect the growth and apoptosis of MDS cells in vivo, we conducted NOD/SCID mouse models in which mice were subcutaneously injected with LV-miR-378-treated SKM-1 cells, LV-controltreated SKM-1 cells and untreated SKM-1 cells.…”

Development of Intermediate-Grade (Mantle Cell) and Low-Grade (Small Lymphocytic and Marginal Zone) Human Non-Hodgkin's Lymphomas Xenotransplanted in Severe Combined Immunodeficiency Mouse Models

“…Recently, better immunodeficient rodent models such as SCID mice have provided an improved second generation (when compared with the earlier nude mice) of preclinical in vivo models for XT studies of a variety of human tumors and the characterization of human neoplastic cell growth in vivo ( Duchosal et al, 1992;Fidler, 1986;Flavell et al, 1996). In the past 3 years, we have been able to xenotransplant a wide range of primary NHL and Hodgkin's disease tumor cells into SCID mouse recipients (Ford et al, 1996;Ford et al, 1998).…”

The Dynamic Character of the BCL2 Promoter i-Motif Provides a Mechanism for Modulation of Gene Expression by Compounds That Bind Selectively to the Alternative DNA Hairpin Structure

“…Statistical significance ( P < 0.05) was evaluated using a two-tailed Student’s t- test except for the in vivo study as previously described . Data are presented as mean ± standard error from three independent experiments.…”